Shionogi Plans Greater Presence In U.S., U.K. Markets
This article was originally published in PharmAsia News
Executive Summary
Japan's Shionogi plans to concentrate on the foreign market with an aim to triple the foreign share of its overall sales. Foreign business currently accounts for only 10 percent of Shionogi sales and its goal is to boost that amount to 30 percent. The firm plans to create a wholly owned subsidiary for development in the United Kingdom and apply for approval of three products in the United States in 2011. To market those drugs two years later, Shionogi is considering acquisition of a midsize U.S. drug maker. The drugs include its first product developed abroad, an obesity treatment, now in Phase III trials. (Click here for more - a subscription may be required